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ABBREVIATIONS 
CBA: Cytometric Bead Array 
CCL-2: chemokine (C-C) motif ligand 2 
CD: cluster of differentiation 
DAMPs: damage-associated molecular patterns 
ELISA: Enzyme-Linked Immuno Sorbent Assay 
FIGO: International Federation of Gynecology and Obstetrics 
Gal-1: galectin-1 
IDO: indoleamine 2,3 dioxygenase 
IL: interleukin 
iNOS: inducible nitric oxide synthase 
MDSC: myeloid-derived suppressor cells 
MHC: major histocompatibility complex 
OS: overall survival 
PFS: progression-free survival 
STIC: serous tubal intraepithelial carcinomas 
TAA: tumor associated antigens 
TAM: tumor-associated macrophages 
TGF-β: transforming growth factor beta 
Treg: regulatory T cells 
VEGF: vascular endothelial growth factor 
 
ABSTRACT 
Neoplastic cells can escape immune control leading to cancer growth. Regulatory T cells (Treg), myeloid-
derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) are crucial in immune escape. TAM 
are divided based on their immune profile, M1 are immunostimulatory while M2 are immunosuppressive. 
Research so far has mainly focused on the intratumoral behavior of these cells. This study, on the other hand, 
explored the systemic changes of the key metabolites [IL-4 (interleukin), IL-13, arginase, IL-10, VEGF-A (vascular 
endothelial growth factor), CCL-2 (chemokine (C-C) motif ligand 2) and TGF-β (transforming growth factor)] 
linked to Treg, MDSC and TAM during the course of the disease in ovarian and fallopian tube cancer patients. 
Serum samples were therefore analyzed at diagnosis, after (interval)-debulking surgery and after 
chemotherapy (paclitaxel-carboplatin). We also determined galectin-1, involved in angiogenesis and tumor-
mediated immune evasion. We found significantly lower levels of IL-10, VEGF-A, TGF-β and arginase and higher 
levels of galectin-1 after chemotherapy compared to diagnosis. After debulking surgery, a decrease in IL-10 was 
significant. Galectin-1 and CCL-2 appeared independent prognostic factors for progression-free and overall 
survival (multivariate analysis). These results will help us in the decision making of future therapies in order to 
further modulate the immune system in a positive way. 
Introduction 
Ovarian cancer is the second most frequent pelvic gynaecological cancer and the most common cause of 
gynaecological cancer-associated death among women.1 In most women the disease is diagnosed in an 
advanced stage, which correlates with a poor prognosis and a high recurrence risk. The standard of care 
remains debulking surgery in combination with platin-based chemotherapy. This consists of either 
primary debulking surgery and adjuvant chemotherapy or neoadjuvant chemotherapy followed by 
interval debulking surgery, depending on FIGO stage and predictive factors concerning residual 
macroscopic disease after surgery.2 Tubal cancer on the other hand, is very rare with an incidence of 0.41 
cases per 100.000 women in the U.S. Since the discovery of the serous tubal intraepithelial carcinomas (STIC) 
and a recent review discovering only few differences between primary fallopian tube cancer and primary 
ovarian cancer, tubal cancer was and still is treated like ovarian cancer (For a review see refs 3-4). 
Current evolutions in anti-cancer research have confirmed that the immune system can control cancer. If 
cells transform into (pre-) cancerous cells the host responds to the expressed tumor antigens and damage-
associated molecular patterns (DAMPs) with an innate and adaptive immune response. This often leads to 
elimination of the neoplastic cells or to equilibrium. In this situation, tumor cells are not eliminated by the 
immune system, but reside in a dormant state.5,6 Due to the continuous immune pressure, more immune-
resistant tumor cells will arise.  A myriad of events will occur: 1/ tumor associated antigens (TAA) and 
major histocompatibility complex (MHC) molecules are lost; 2/ chronic inflammation at the tumor site 
leads to continuous activation of peripheral T cells and induces the development of regulatory T cells 
(Treg). In the tumor microenvironment certain chemokines such as chemokine (C-C) ligand-2 (CCL-2) and 
CCL-22 lead to the trafficking of Treg, MDSC (myeloid-derived suppressor cells) and monocytes into the 
tumor. Further expansion of the Treg population is enhanced (5) through the presence of several 
immunosuppressive factors such as indoleamine 2,3 dioxygenase (IDO) and transforming growth factor 
beta (TGF-β); 3/ MDSC accumulate in the tumor microenvironment through the presence of vascular 
endothelial growth factor (VEGF), CCL-2, TGF-β and other chemokines;7,8 4/ monocytes infiltrate into the 
tumor and differentiate into TAM’s (tumor-associated macrophages). Initially, they will present an M1 
phenotype (CD86+, MHCII+), leading to anti-tumor immunity by initiating the adaptive immune response. 
Once hypoxia and immunosuppression take the upper hand, there is a switch to the M2 phenotype 
(CD163+, CD206+). Although this creates new points of action for immunotherapy, this switch will lead to 
further immunosuppression and promotion of tumor growth, through the production of several 
immunosuppressive cytokines, such as interleukin (IL)-4, IL-10, IL-13, VEGF, CCL-2 and TGF-β.10 In the 
end, this combination will result in a strong immune suppressive environment, leading to immune escape. 
Tumor cells can proliferate and the tumor becomes clinically apparent.  
Until now, ovarian cancer research has primarily focused on tumor tissue, with a large focus on genetic 
changes. Moreover, immunological changes so far have only been studied in tumor tissue. Nevertheless, 
since ovarian cancer is a widespread metastatic disease, one can appreciate that the analysis of the 
systemic immune changes is crucial. One way to look at the changes in the immune suppressive milieu is 
by looking at the metabolites produced by tumor cells and immune suppressive cells. Table 1 gives an 
overview on what is currently known about a selection of them. Additionally, we analyzed galectin-1 (gal-
1), a glycan-binding protein. It has a natural immunosuppressive function and a pivotal role in the 
maintenance of self-tolerance and T cell homeostasis. Via interaction with -galactoside expressing 
glycoproteins on the T cell surface, gal-1 can negatively regulate T cell survival, antagonize T cell signaling and 
block pro-inflammatory cytokine secretion.
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 Furthermore, gal-1 blunts T cell responses via promoting 
accumulation and expansion of Tregs.12 It is overexpressed by numerous malignant cell types, including 
ovarian cancer, by activated vascular endothelial cells, by normal activated T cells and by Treg. In anti-
VEGF refractory tumors, gal-1 has been documented to bind VEGF receptor 2 and to maintain 
angiogenesis.13 The role of gal-1 has been studied in ovarian cancer and is associated with a poor 
prognosis and it accelerates the proliferation and invasive capacity of the tumor cells.14 
Results 
Patient characteristics 
An overview of the patient characteristics and outcome is given in table 2 and figure 1. The majority 
(90%) was diagnosed with serous ovarian carcinoma at an advanced stage (FIGO stage IIIC and IV) and 
79% of patients had one or more relapses. The median follow up time was 47 months. The median PFS 
was 16 months, the median OS was 50 months (figure 1). We can therefore conclude that our study 
population was a representative group.  
Immunosuppression at diagnosis of ovarian cancer patients versus healthy controls 
First, we compared the metabolite values between naïve samples (diagnosis of ovarian cancer without 
invasive procedure, most commonly by diagnosis at ultrasound) (n=32) and samples taken after 
diagnostic laparoscopy (n=23). There were no significant differences in the values between these two time 
points (Table 3). Therefore, we will combine the two groups in further analyses and we will refer to them 
as one group “at diagnosis”. In case we had patients with measurements at both occasions, the average 
value was used (this was the case in 5 patients). Two metabolites (TGF-β and arginase) could not be 
measured in two samples (naïve and laparoscopy) because of the small sample volume. 
Serum samples from 50 patients “at diagnosis” were compared with serum samples from 10 healthy 
donors. IL-10 (p < 0.001) and TGF-β (p=0.021) were significantly higher in patients compared to controls. 
We could not observe a decrease change of gal-1 with increasing age of healthy controls (p=0.135).15  
Immunosuppression in ovarian cancer patients at diagnosis versus after three chemotherapy cycles 
A total of 37 patients received 3 cycles of paclitaxel-carboplatin and 3 patients received 3 cycles of 
carboplatin in monotherapy. We found significant lower levels of IL-10 (p < 0.001), VEGF (p = 0.040), TGF-
β (p < 0.001) and arginase (p < 0.001) and higher levels of gal-1 (p = 0.016) after chemotherapy compared 
to diagnosis (Table 3).  After exclusion of the 7 patients who received AMG 386 or placebo together with 
carboplatin-paclitaxel in study (BGOG-ov7), statistical results did not change (data not shown). After 
exclusion of patients treated with carboplatin only (since this is not the standard of care in ovarian cancer 
treatment), IL-10, TGF-β, arginase and gal-1 kept their statistical significance.  
Immunosuppression in ovarian cancer patients at diagnosis versus after (interval) debulking surgery 
We obtained 15 samples after primary debulking surgery and 19 samples after interval debulking surgery. 
In two serum samples arginase and TGF-β could not be analyzed, because the sample volume was not 
sufficient. In both patient groups a decreased level of IL-10 (p < 0.001) was demonstrated compared to 
patients measured at diagnosis.  
Longitudinal evolutions in metabolite values 
Of 40 patients we gathered more than one sample during their disease course, enabling us to measure 
longitudinal evolutions in metabolite values. The composition of the groups is presented in Table 4. We 
can discriminate 3 groups: group 1/ 17 samples from patients at diagnosis and after 3 cycles of paclitaxel-
carboplatin. Here we found significant lower levels of IL-10 (p = 0.0005), VEGF (p = 0.0079), TGF-β (p 
0.0092), arginase (p = 0.0093) and CCL-2 (p = 0.0093). There was a trend for increasing gal-1 levels (p = 
0.0797); group 2/ 11 and 7 samples from patients at diagnosis and respectively after primary debulking 
surgery and interval debulking surgery. Comparable to the whole group of samples, IL-10 showed 
decreased levels (p = 0.0049 and p = 0.0781); group 3/ from 4 patients we gathered measurements taken 
after treatment (1 patient after primary debulking and adjuvant chemotherapy, 1 patient after 3 cycles of 
neoadjuvant chemotherapy, after interval debulking and after 3 cycles of adjuvant chemotherapy and 2 
patients after adjuvant chemotherapy) and at recurrence. No systematic differences in metabolite values 
were found between these two groups.  
Immunosuppressive metabolites and tumor grade 
Metabolite values at diagnosis did not differ significantly between high grade and low grade ovarian 
cancers.  
Progression free and overall survival 
The association between metabolite values and PFS and OS was studied in a multivariable (including FIGO 
stage and residual disease after cytoreductive surgery as prognostic variables) analysis. Gal-1 and CCL-2 
appeared to be independent prognostic factors for both PFS and OS. In detail, higher values of gal-1 were 
associated with an increased risk of progression (p = 0.0293) and death (p = 0.0096). For CCL-2 a 
quadratic effect appeared, implying that both lowest and highest values of CCL-2 were associated with 
increased risk of progression (p = 0.0294) and death (p = 0.0377) (Figure 2).   
Discussion 
The role of the immune system in the development and recurrence of cancer is crucial. In ovarian cancer, 
studies so far have investigated the intratumoral presence of immune suppressive cells. This study is the 
first one to suggest an important systemic role for Treg, MDSC and TAM, based on the presence of their 
metabolites in serum allowing us to gain insight in overall immunosuppression. Moreover, we could 
demonstrate that conventional standard therapies (radical debulking surgery and paclitaxel-carboplatin 
based chemotherapy) significantly reduce these metabolite levels and that gal-1 and CCL-2 independently 
worsened the PFS and OS.  
As demonstrated in Table 1, the existing immunological studies in ovarian cancer are scarce, do not cover 
the total immune suppressive repertoire and are limited in sample size (mean 61.5, range 16 to 130 
patients). However, our results certainly confirm previous findings: decrease of IL-10 after 
cytoreduction16 and an increase of IL-10, TGF-β and arginase in ovarian cancer patients at diagnosis.17,18 In 
contrast to reported findings on VEGF, we could not correlate the presence of VEGF to prognosis nor did 
we see an increase after surgery.19-23 
We found that galectin-1 serum levels increased after three cycles of paclitaxel-carboplatin. Similar 
finding have already been described for glioblastoma, where gal-1 expression increased in endothelial and 
glioma cells after radiotherapy and after treatment with temozolomide.24,25 This seems contradictory, 
however, in lung and ovarian cancer, gal-1 overexpression appears to promote chemotherapy resistance 
and downregulation of gal-1 expression can sensitize tumor cells to platin-based chemotherapy.14,26,27 In 
ovarian cancer gal-1 could possibly mediate these effects through activation of the H-Ras/Raf-1/ERK 
pathway.14 The group of Le Mercier et al. suggested that increased gal-1 levels therefore seem to be 
representative of defense mechanisms against cytotoxic drugs, such as chemotherapy, and that gal-1 could 
consequently be of major importance in chemotherapy resistance.24 Both our results in gal-1 (increase 
after chemotherapy and being an independent prognostic factor) support this theory. 
Literature provides mixed data about CCL-2 levels in the serum of ovarian cancer patients. Compared to 
healthy controls, both lower levels28,29 as higher levels of CCL-230,31 are reported. Some studies claim that 
higher levels are associated with advanced disease.30,31 In our study population we showed that both the 
lowest as well as the highest serum levels of CCL-2 were independently associated with a poor prognosis. 
A possible explanation might lay in the findings that CCL-2 can act dichotomously. In a mammary 
carcinoma model for example, Li et al. found that CCL-2 seemed to stimulate immunosurveillance of 
developing malignancies and metastatic cells. However, after a long-term inhibition of CCL-2 they 
observed an increase of metastatic burden. On the other hand CCL-2 also appeared to enhance the 
progression of primary lesions that had already reached a ‘critical mass’.32 This finding might explain the 
measurements of CCL-2 in our study, however, it also implies cautiousness when it should be used in a 
diagnostic or therapeutic setting.  
This is – to the best of our knowledge - the first study in serum that explores the different aspects of 
immune suppression at diagnosis and after standard treatment in ovarian cancer patients. The next step 
to study the systemic changes in the immune system in ovarian cancer is a prospective inclusion of 
ovarian cancer patients from the moment of diagnosis until palliation, not only at the serum level but also 
at the cellular level. This type of study will be able to reveal what type of immune suppressive 
cells/systemic immune suppression will be most crucial during what point in the disease course. 
Hopefully this insight can help us to better optimize and time the best therapy at the best moment in the 
future. 
Materials and methods  
Serum samples 
After approval of the local ethical committee, a total of 135 serum samples, obtained in 80 patients with 
the histopathological diagnosis of ovarian/tubal cancer, were analyzed. Samples were collected from 
2010-2014, after written informed consent. They were gathered at diagnosis (n=32), after diagnostic 
laparoscopy (n=23), after primary debulking (n=15) [all without macroscopic tumor post-surgery], after 
three neoadjuvant cycles of paclitaxel-carboplatin (n=40), after interval debulking (n=19) [17 had no 
macroscopic remaining tumor post-surgery, 2 had an unresectable metastasis of 1-2cm post-surgery] and 
at diagnosis of recurrent disease (n=6). In 7 patients, neoadjuvant paclitaxel-carboplatin was given in the 
BGOG-OV7 study, implying that the chemotherapy was associated with the simultaneous administration of 
AMG386 (a selective angiopoietin-1/-2 neutralizing peptibody) or placebo. At present, the study has not 
been unblinded yet. Samples after laparoscopy, chemotherapy, debulking or interval debulking were 
collected respectively 13, 33, 26.5 and 21 days (median) after surgery/chemotherapy. Of 40 patients, two 
or more consecutive samples were available. In addition, serum was collected prospectively after approval 
of the local ethical committee from 10 healthy age-matched controls, without ovarian pathology.  
Serum was collected in BD Vacutainer® Serum Tubes containing silica (ref 369032 and 367896, BD) and 
kept at 4°C until centrifugation. Samples were centrifuged at 2700-3000 rpm during 10 minutes. This was 
done in the majority of samples within 48 hours after prelevation. However, 12 samples (8%) could only 
be processed 3-8 days after prelevation (mean 4.5 days). Resulting serum was collected and stored in 
aliquots at -80°C until further analysis.   
Cytometric Bead Assay (CBA) 
All serum samples were analyzed on the presence of IL-4, IL-10, IL-13, IL-17, IFN-γ, VEGF-A, TGF-β and 
CCL-2 by the use of CBA flex sets (ref respectively 558272, 558274, 558450, 562151, 561515, 558336, 
560429, 558287 - BD), according to the firms’ guidelines in 96-well plates. Samples were acidified prior to 
the analysis for TGF-β; samples (except for TGF-) were used undiluted. Samples were analyzed by the 
LSR Fortessa flow cytometer (BD).  Analysis was performed by FLOWJO software. 
Enzyme-linked immunosorbent Assay (ELISA)  
All serum samples were analyzed for the presence of gal-1 by ELISA (anti-gal-1 from R&D, ref AF1152 and a 
biotinylated goat antihuman galectin-1 antibody (R&D with ref BAF1152)). Our protocol was published earlier.
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Arginase-1 activity assay 
Arginase-1 was determined to give an impression of MDSC and TAM activity. L-arginine is a substrate for 
two enzymes, iNOS (that generates nitric oxide) and arginase-1 (that converts L-arginine in urea and L-
ornithin). MDSC show an increased activity of arginase-1 and iNOS, resulting in a relative depletion of L-
arginine in the micro-environment and a relative increase in NO. This results in the inhibition of T cell 
proliferation and function. In all serum samples, arginase-1 activity was measured, through determination 
of the urea content using the QuantiChrom™ Arginase Assay Kit (ref DARG-200 - Bioassay Systems) 
following the manufacturer’s protocol.  
Statistical methodology 
Normality was assessed by visual inspection of the histograms of metabolite values. The Mann-Whitney U test 
was used to compare metabolite values between two groups of patients evaluated at different 
measurement occasions. The Wilcoxon signed-rank test was used to analyze evolutions of metabolites 
within subsets of patients with longitudinal measurements. The Cox proportional hazard model was used 
to analyze the association between metabolite values at diagnosis and progression-free survival (PFS) and 
overall survival (OS). Both linear and quadratic trends were tested. 
All statistical tests are two-sided and a 5% significance level is assumed for all tests. A large number of 
statistical tests was performed. Given the exploratory nature of this study, no correction for multiple 
testing was applied. All analyses have been performed using SAS software, version 9.4 of the SAS System 
for Windows. 
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Figure 1. Survival of ovarian cancer patients included in the study group (n=80) 
 
Legend: A. Progression-free survival (months); B. Overall survival (months) 

















Figure 2. Quadratic effect of CCL-2 expression in ovarian cancer patients at diagnosis 
 
Legend: Values of CCL-2 in relation to the progression-free survival (A) and the overall survival (B). The graph 
(univariate analysis) shows a quadratic effect of CCL-2 values in ovarian cancer patients at diagnosis. This 
implicates that both low and high levels of CCL-2 are associated with worse prognosis of ovarian cancer patients 
.  






























Table 1. Overview on immunologic metabolites that can be detected in serum.  
 
 











Table 3. Overview on the presence of metabolites in serum of patients with ovarian cancer at different time 













Table 4. Overview on the presence of metabolites in serum of patients with ovarian cancer at different time 













Table S1. Overview on patient characteristics for the different cohorts (at diagnosis, after chemotherapy, after 
(interval)debulking surgery) 
 
 
 
 
 
 
